5-Amino-1MQ
Also known as: 5-amino 1-methylquinolinium, NNMT Inhibitor
5-Amino-1MQ is a selective inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that is overexpressed in adipose tissue of obese individuals and plays a key role in metabolic regulation. By inhibiting NNMT, 5-Amino-1MQ increases the availability of NAD+ and S-adenosylmethionine (SAM) in fat cells, which activates cellular energy pathways and promotes lipid metabolism. Preclinical studies have demonstrated significant reductions in body weight, fat mass, and adipocyte size without affecting food intake or lean muscle mass — suggesting it targets fat metabolism directly rather than suppressing appetite. It represents a novel mechanism for weight management distinct from GLP-1 agonists.
Extensive clinical evidence
Well-tolerated with minimal side effects
How It Works
5-Amino-1MQ selectively inhibits NNMT, an enzyme overexpressed in obese adipose tissue. By blocking NNMT, it increases intracellular NAD+ and SAM availability in fat cells, activating sirtuin-mediated metabolic pathways and promoting lipid oxidation and energy expenditure without affecting appetite or lean mass.
Key Benefits
- Reduces fat mass without affecting muscle
- Increases cellular NAD+ in adipose tissue
- Promotes fat cell energy expenditure
- No appetite suppression side effects
- Novel mechanism complementary to GLP-1 agonists
- May improve metabolic biomarkers
Who May Benefit
- Individuals struggling with stubborn fat despite diet and exercise
- Patients on GLP-1 therapy seeking complementary fat loss support
- People with metabolic syndrome or insulin resistance
- Those wanting body recomposition without muscle loss
Dosage & Administration
Expected Timeline
Early metabolic changes in 2-4 weeks. Noticeable fat loss at 4-8 weeks. Optimal results with full 8-12 week cycle.
Safety Information
Possible Side Effects
Contraindications
Dr. Taylor's 2 Cents
“5-Amino-1MQ is the most interesting weight management compound that ISN'T a GLP-1 agonist. It works by a completely different mechanism — blocking the NNMT enzyme that's overactive in fat tissue. What excites me is that it targets fat specifically without touching muscle mass or suppressing appetite. I use it alongside GLP-1 therapy for patients who want to maximize fat loss while preserving lean tissue. The preclinical data on body composition changes is impressive.”
Discuss with Dr. Taylor →Frequently Asked Questions
What is 5-Amino-1MQ?
How is it different from GLP-1 medications like semaglutide?
Does it cause muscle loss?
How is it administered?
Is 5-Amino-1MQ FDA approved?
What are the side effects?
Published Research
Nicotinamide N-methyltransferase inhibition reverses diet-induced obesity in mice
Neelakantan H, Vance V, Wetzel MD, et al. · Biochemical Pharmacology (2020)
Key Finding: NNMT inhibition with 5-Amino-1MQ significantly reduced body weight and fat mass in diet-induced obese mice without affecting food intake or lean muscle mass.
Small molecule inhibition of nicotinamide N-methyltransferase selectively reduces adiposity
Neelakantan H, Brightwell CR, Graber TG, et al. · Biochemical Pharmacology (2019)
Key Finding: 5-Amino-1MQ treatment reduced adipocyte size by 30%, decreased lipid accumulation, and increased intracellular NAD+ and SAM levels, activating cellular energy expenditure pathways in fat tissue.
NNMT: A key metabolic regulator in obesity and metabolic disease
Pissios P · Trends in Endocrinology & Metabolism (2024)
Key Finding: NNMT overexpression in white adipose tissue correlates with obesity severity, and pharmacological inhibition restores metabolic flux through NAD+ salvage pathways, reducing fat mass independent of caloric restriction.
Protocols Featuring 5-Amino-1MQ
Want personalized guidance?
Consult with Dr. Patrick Taylor for a comprehensive evaluation and personalized protocol.
Book a ConsultationMedical Disclaimer: This information is for educational purposes only and is not medical advice. Consult a healthcare provider before starting any peptide protocol.